|
NR. 3(I)/2007
|
|
|
|
|
|
|
|
|
Zastosowanie
inhibitorów angiogenezy w leczeniu wysiękowej postaci
zwyrodnienia plamki związanego z wiekiem
Antiangiogenic Agents Use in the Treatment of Exudative Form of
Age-Related Macular Degeneration
Magdalena Ulińska, Anna I. Borucka,
Jerzy Szaflik
Katedra i Klinika Okulistyki II Wydziału Lekarskiego Akademii
Medycznej w Warszawie
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik |
|
|
|
|
|
|
|
| Summary: |
One of the goals of huge
importance in retinology is looking for new procedures
to treat Age-Related Macular Degeneration. While dry
form of AMD is still almost untreatable, wet form can be
successfully treated by repeated intravitreal injections
of anti-VEGF agents. This kind of treatment is superior
to previous methods such as laser photocoagulation, PDT
or TTT, because it gives possibility not only to reduce
visual impairment, but to improve visual acuity as well.
In the paper there is a short update on the role of VEGF
in the development of wet AMD. Then the currently used
anti-VEGF agents: pegaptanib sodium (Macugen®),
ranibizumab (Lucentis®) and bevacizumab (Avastin®) are
presented. The presentation focuses on their mechanism
of action and on main results of clinical trials to show
efficacy of such treatment.
Finally some general rules are given that should be
taken into consideration in intravitreal injection
procedures. |
| |
|
| Key words: |
antiangiogenic agents,
intravitreal injection, age-related macular degeneration,
AMD, choroidal neovascularization. |
|
|
|
|
|
|
|
|
